#CMSC17 – Relapse After First Lemtrada Course No Indication of Poor Long-Term Outcome, Study Finds
Multiple sclerosis (MS) patients who experienced a relapse between their first and second rounds of Lemtrada (alemtuzumab) had good treatment outcomes over the long run, according to a Phase 3 clinical trial. Those who relapsed after their first round ended up with annual relapse rates similar to those who didn’t…